(Q37754477)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20476851%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

review article

1 reference

title

Emerging drugs for partial onset seizures (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20476851%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20476851%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Ahmad Beydoun

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20476851%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Samir Atweh

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20476851%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Bassel Abou-Khalil

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20476851%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

English

0 references

publication date

1 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20476851%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Emerging Drugs

2 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20476851%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20476851%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20476851%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

415-431

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20476851%20AND%20SRC:MED&resulttype=core&format=json

The descriptive epidemiology of epilepsy-a review

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

The social and economic impact of epilepsy in Zambia: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Prevalence of self-reported epilepsy in a multiracial and multiethnic community in New York City.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Prevalence of treated epilepsy in western medicine among the adult population in Taiwan: a study conducted using antiepileptic drug prescription data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Cost of epilepsy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Employers' attitudes to employment of people with epilepsy: still the same old story?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Epilepsy stigma and stigma by association in the workplace

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Molecular targets for antiepileptic drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Seizure reduction and quality of life improvements in people with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Effectiveness of first antiepileptic drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Likelihood of seizure remission in an adult population with refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Volume and market share of anti-epileptic drugs in The Netherlands: impact of new drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Basic mechanisms of epilepsy: targets for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Emerging concepts in the pathogenesis of epilepsy and epileptogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Pharmacological management of epilepsy: recent advances and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Eslicarbazepine acetate (BIA 2-093).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Efficacy and tolerability of pregabalin in partial epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Brivaracetam: a rational drug discovery success story

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

21 January 2018

Brivaracetam (UCB 34714)

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

21 January 2018

Carisbamate (RWJ-333369)

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Randomized, controlled, dose-ranging trial of carisbamate for partial-onset seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Molecular and cellular mechanisms of pharmacoresistance in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Prevalence and Pattern of Epilepsy Treatment in Different Socioeconomic Classes in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.492394

10.1517/14728214.2010.492394

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20476851%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference